Home Cart Sign in  
Chemical Structure| 106-24-1 Chemical Structure| 106-24-1

Structure of Geraniol
CAS No.: 106-24-1

Chemical Structure| 106-24-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Geraniol is an inhibitor of glutathion S transferase with anticarcinogenic property.

Synonyms: β-Geraniol; NSC 9279; (E)-Geraniol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Geraniol

CAS No. :106-24-1
Formula : C10H18O
M.W : 154.25
SMILES Code : C/C(C)=C\CC/C(C)=C/CO
Synonyms :
β-Geraniol; NSC 9279; (E)-Geraniol
MDL No. :MFCD00002917
InChI Key :GLZPCOQZEFWAFX-JXMROGBWSA-N
Pubchem ID :637566

Safety of Geraniol

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H303-H315-H317-H318-H402
Precautionary Statements:P261-P264-P272-P273-P280-P302+P352-P305+P351+P338+P310-P312-P333+P313-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human PC-3 prostate cancer cells 2 mM 24 hours Evaluate the effects of HA-SS-Geraniol on the cell cycle of PC-3 cells. The results showed that treatment with HA-SS-Geraniol arrested the cells in the G2 phase (21.97%) compared with the control group (9.55%) and the geraniol group (9.00%). Int J Nanomedicine. 2024 Jan 6;19:155-169
Human PC-3 prostate cancer cells 2 mM 24 hours Evaluate the apoptotic effects of HA-SS-Geraniol on PC-3 cells. The results showed that the apoptotic rate after HA-SS-Geraniol treatment was 48.50 ± 0.10%, nearly 8-fold higher than the control group. Int J Nanomedicine. 2024 Jan 6;19:155-169
Human PC-3 prostate cancer cells 2 mM 24 hours Evaluate the effects of HA-SS-Geraniol on mitochondrial membrane potential in PC-3 cells. The results showed that HA-SS-Geraniol significantly enhanced mitochondrial membrane potential loss effects. Int J Nanomedicine. 2024 Jan 6;19:155-169
Human PC-3 prostate cancer cells 13.95 mM 48 hours Evaluate the cytotoxic effects of HA-SS-Geraniol on PC-3 cells. The results showed that HA-SS-Geraniol exhibited significant anti-prostate cancer effects. Int J Nanomedicine. 2024 Jan 6;19:155-169
SH-SY5Y cells 0.84 µg/mL 24 hours Geraniol significantly reduced reactive oxygen species (ROS) levels after 6-OHDA treatment and increased ATP concentration. Antioxidants (Basel). 2024 Jul 29;13(8):917
Acetylcholinesterase (AChE) 16.2, 32.4, 64.8, 97.2, 129.7 μM 20 minutes Geraniol inhibited AChE activity in a dose-dependent manner with an IC50 value of 98.06±3.92 μM, indicating that geraniol is a competitive inhibitor of AChE. Cells. 2021 Dec 14;10(12):3533
PC12 cells 20 µM 24 hours To evaluate the protective effect of geraniol on OGD/R-induced PC12 cells, results showed geraniol significantly increased cell viability and reduced apoptosis Int J Mol Sci. 2022 Dec 29;24(1):544

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Subcutaneous xenograft tumor model 100 mg/kg (Geraniol equivalent) 5 weeks Evaluate the anti-tumor effects of HA-SS-Geraniol in vivo. The results showed that the HA-SS-Geraniol group had an average tumor volume half as low as the control group, with a tumor growth inhibitory ratio of 54.0%. Int J Nanomedicine. 2024 Jan 6;19:155-169
Wistar rats Isoproterenol-induced myocardial infarction model Oral gavage 100 or 200 mg/kg Once daily for 14 days Geraniol ameliorates oxidative, inflammatory, and apoptotic alterations in isoproterenol-induced cardiotoxicity by modulating the Keap1/Nrf2/HO-1 and PI3K/Akt/mTOR pathways Antioxidants (Basel). 2020 Oct 12;9(10):977
Sprague-Dawley rats Middle cerebral artery occlusion reperfusion model Intraperitoneal injection 200 mg/kg Administered for 5 consecutive days before surgery and once again after surgery To investigate the protective effect of geraniol against cerebral ischemia-reperfusion injury, results showed geraniol significantly reduced cerebral infarct volume and improved neurological function Int J Mol Sci. 2022 Dec 29;24(1):544

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.48mL

1.30mL

0.65mL

32.41mL

6.48mL

3.24mL

64.83mL

12.97mL

6.48mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories